

Author Index

- Abman, S. H., 387
 Allan, L. D., 323, 324, 380
 Ariagno, R. L., 247
- Barrington, K. J., 59
 Beckman, J. S., 37
 Bian, K., 2
 Billiar, T. R., 46
 Brown, S. A., 373
 Budorick, N. E., 352
 Busse, R., 15
- Charnock-Jones, D. S., 82
 Chaudhuri, G., 1
 Clark, D. E., 82
 Comstock, C. H., 331
 Cornblath, M., 91, 136
 Czeisler, C. A., 299
- Davis, K., 2
 DeBaun, M. R., 164
 Devine, P. C., 343
 Dvorak, H. F., 75
- Espey, M. G., 20
 Estévez, A. G., 37
- Ferreira, S. H., 7
 Fiascone, J., 385, 445
 Fielder, A. R., 291
 Finer, N. N., 59
 Fisslthaler, B., 15
 Fleming, I., 15
 Frantz, I. D., III, 385
- Gilstrap, L. C., III, 196, 200
 Giraud, G. D., 11
 Glaser, B., 150
 Greenspan, J. S., 396
 Gross, S. S., 42
 Gustafsson, J-Å., 66
- Hao, H., 232
 Hattori, Y., 42
 He, Y., 82
 Henriksen, T., 29
 Hollier, L. M., 204
 Huang, P. L., 87
- Ichord, R., 136
- Jacobson, S-L., 11
 Jaffe, R. B., 79
- Kalhan, S., 94
 Kennaway, D. J., 258
 Kibbe, M. R., 51
 Kim, J. O., 221
 King, A. A., 164
 Kinnala, A., 116
 Kinsella, J. P., 387
 Korvenranta, H., 116
- Lee, Y. C., 2
 Lemmer, B., 280
 Li, J., 46
 López-Jaramillo, P., 33
- McNellis, D., 1
 Martin, E., 2
 Mayes, L. C., 267
 Millman, S. L., 352
 Miranda, K. M., 20
 Mirmiran, M., 247
 Morton, M. J., 11
 Moseley, M. J., 291
 Murad, F., 2
 Muratore, C. S., 418
- Ozand, P. T., 172
- Parimi, P., 94
 Parkkola, R., 116
 Phelan, J. P., 221
 Pschirrer, E. R., 215
- Rais-Bahrami, K., 406
 Ramin, S. M., 195, 200
 Reppert, S. M., 243
 Rivkees, S. A., 231, 232
 Roberts, J. D., Jr., 55
 Roberts, J. M., 24
- Schulze, A., 429
 Schwartz, R., 91, 120
 Shaffer, T. H., 396
 Shanahan, T. L., 299
 Shaul, P. W., 70
 Short, B. L., 406
 Simpson, L. L., 323, 343, 360
 Smith, S. K., 82
 Spong, C. Y., 1
- Teng, R., 37
 Teramo, K. A., 120
 Thornburg, K. L., 11
 Tume, N., 42
 Tzeng, E., 51
- Vannucci, R. C., 107
 Vannucci, S. J., 107
 Viera, L., 37
- Welch, K. K., 373
 White, N., 164
 Wilson, J. M., 418
 Wink, D. A., 20
 Wolfson, M. R., 396
- Xie, L., 42
- Yeomans, E. R., 215
- Zapol, W. M., 55

Subject Index

- Abdominal surgery, maternal, effects of, on
 - obtention of four-chamber view of heart during midtrimester screening, 333
- Accuracy of routine midtrimester screening, 331-332
- ACE(s) (angiotensin-converting enzyme), history and relevance of, 7-10
- ACE (angiotensin-converting enzyme) inhibitors, effects of, on 24-hour pattern of hypertension, 286
- Acid/base status in fetal diagnosis of neurological injury, 207
- Acidemia, neonatal hypoglycemia associated with, 175-177
 - methylnmalonic acidemia, 176-177, 187
 - propionic acidemia, 175-176, 187
- Acidic protein, CSF glial fibrillary, as marker of neurological injury, 208
- Aciduria, neonatal hypoglycemia associated with glutaric aciduria type 2, 183-187
 - 3-MGC, 172
- Activation of endothelial eNOS, *see* Endothelial nitric oxide synthase, rapid activation of
- Acute asphyxia, fetal, in CP, diagnosis of
 - with meconium-stained amniotic fluid, 206
 - with reactive admission test, fetal brain damage subsequent to, 223-225
- Acute respiratory distress syndrome (ARDS), neonatal
 - inhaled NO for, 56
 - see also* Neonatal respiratory disease, management of
- Acylcarnitine translocase/carnitine deficiency, neonatal hypoglycemia associated with, 184, 186, 187
- Acyl-coenzyme A dehydrogenase deficiency, *see* 3-Hydroxy-acyl-coenzyme A dehydrogenase deficiency, neonatal hypoglycemia associated with; Medium chain acyl-coenzyme A dehydrogenase deficiency; Multiple acyl-coenzyme A dehydrogenase deficiency; Very long chain acyl-coenzyme A dehydrogenase deficiency
- Adenomatous hyperplasia, *see* Focal hyperinsulinism, neonatal
- Adjustments in computer-assisted mechanical ventilation, 430-432
 - of FiO₂ to control SpO₂, 430-432
 - of peak inspiratory pressure to control tidal volume, 432
 - of respirator rate to control minute ventilation, 432
- Administration of melatonin to children, 263-264
- Admission test, reactive, fetal diagnosis of acute asphyxia in CP with, 222-225
- Adult disease, melatonin and fetal onset of, 261
- Adverse effects, *see* Complications
- Afferent pathways of SCN, 301
- Age
 - postnatal, and use of iNO, 388
 - see also* Gestational age
- Airflow, monitoring of, in computer-assisted mechanical ventilation, 441
- Airway pressure/volume relationship, monitoring of, in computer-assisted mechanical ventilation, 441-442
- Alanine, neonatal GNG from, 101-102
- Alkalinization to permissive hypercapnia, hyperventilation and, in CDH, 422-423
- Alpha (α)-proteinase inhibitor therapy, postnatal, CLD prevention with, 455-456
- Alternate substrates for glucose metabolism in developing brain, 111-112
- Amino acid disorders, *see* Hypoglycemia, neonatal, associated with organic and amino acid disorders
- Amniotic fluid, meconium-stained, fetal diagnosis of brain injury with, 206
- Amplitude of circadian oscillator, 303-304
- Anatomy, *see* Neuroanatomy
- Angiogenesis, 75-86
 - placental, VEGF gene expression and, 82-86
 - and reproductive physiology, 79-81
 - VPF/VEGF and angiogenic response, 75-78
- Angiogenic growth factor, *see* Vascular endothelial growth factor gene family expressed in placenta, placental angiogenesis and
- Angiotensin-converting enzyme(s) (ACE), history and relevance of, 7-10
- Angiotensin-converting enzyme (ACE) inhibitors, effects of, on 24-hour pattern of hypertension, 286
- Antenatal prevention of CLD, 447-448
 - with anti-inflammatory therapy, 447
 - with TRH, 447-448
- Anti-inflammatory therapy
 - antenatal, in CLD prevention, 447; *see also* Glucocorticoid therapy, CLD prevention with
 - with PFC liquids, 402
- Antioxidants, postnatal, CLD prevention with, 454
- Antiproliferation of VSMCs, *see* Vascular smooth muscle cells, NO-mediated antiproliferation of
- Aortic outflow tract, routine midtrimester screening of, 333-334
- Apgar score in diagnosis of CP, 206-207
- Apoptosis, *see* Nitric oxide, role of, in apoptosis
- Arch, normal, on practical fetal heart scan, 329
- ARDS, *see* Acute respiratory distress syndrome, neonatal
- Arginine
 - effects of, on NO-cGMP formation and NOS enzymes, 3-4
 - preferred source of, for high-output NO synthesis in blood vessels, 42-45
- Arginine-vasopressin (AVP), cord blood, as marker of neurological injury, 208
- Arousal states, developmental perspective on regulation of, 267-279
 - developmental change in, 272
 - impaired regulation of, 276-277
 - individual differences in response to, 270-271
 - linear and nonlinear response to, 271-272
 - neural circuitry for, 272-276

- physiologic and behavioral responses to, 268-269
and types of arousal situations, 269-270
- Arterial hemoglobin oxygen saturation (SpO_2),
adjustment of FiO_2 to control, in computer-
assisted mechanical ventilation, 430-432
- Arterio-ventricular connections, normal, on practical
fetal heart scan, 327-329
- Aspartic acid, CSF, as marker of neurological injury,
208
- Asphyxia, *see* Fetal asphyxia; Markers of asphyxia in
CP; Neonatal asphyxia
- Assessment
of risks for recurrence of fetal congenital heart
defect, genetic counseling and, 377-378
see also Diagnosis; Evaluation
- Associated conditions
with CP, 196-199
see also Associated conditions, neonatal and specific
conditions
- Associated conditions, neonatal
with CP, 197-199
with FHR patterns in CP, 227
see also Hypoglycemia, neonatal, associated with
organic and amino acid disorders;
Hypoglycemia, neonatal, in BWS
- Asthma bronchiale, chronopharmacotherapy of,
282-283
- Atherosclerosis, preeclampsia and, 25
- Atrial flutter and fibrillation, supraventricular
tachycardias and, 369-371
- Atypical hyperinsulinism (HI), neonatal, 159-161
- Autosomal recessive hyperinsulinism (HI), neonatal,
due to mutations in beta cell K_{ATP} channel
genes, 152-153, 158
- AVP (arginine-vasopressin), cord blood, as marker
of neurological injury, 208
- Axis, heart, evaluation of, with routine midtrimester
screening, 341
- BCAA disorders, *see* Branched chain amino acid
disorders, neonatal hypoglycemia associated
with
- Beckwith-Wiedemann syndrome, *see* Hypoglycemia,
neonatal, in BWS
- Behavioral responses to arousal, 268-269
- Beta (β)-cell K_{ATP} channel gene mutations,
neonatal autosomal recessive
hyperinsulinism due to, 152-153, 158
- Beta oxidation, *see* Mitochondrial β -oxidation and
fatty acid degradation, neonatal hypoglycemia
associated with defective
- Biochemistry
of carnitine/palmitoyl transferase I and II
deficiency, 187
3-hydroxy-acyl-coenzyme A dehydrogenase
deficiency, 182
of MADD, 183, 184
of MCAD deficiency, 179
of VLCAD deficiency, 181
- Biological clock
SCN, 243-245
see also Chronobiology
- Biological functions of NO, 55-56
- Biology
neurobiology of neonatal hypoglycemia, 138-139
see also Chronobiology and entries beginning with
term: Biological
- Biophysical profile, fetal, and diagnosis of fetal
brain injury, 205, 206
- Birth, markers of asphyxia in CP at, 217-218
- Birth weight
CLD incidence by, 446
GNG in VLBW infants, 103, 104
low, *see* Low birth weight
- Blind population, physiologic effects of light on
circadian pacemaker in, 311-312
- Blood pressure, *see* Hypertension
- Blood vessels
arginine and high-output NO synthesis in, 42-45
daughter and mother, VPF/VEGF and formation
of, 77
see also Endothelium-derived hyperpolarizing
factor in coronary arteries; Vasculature and
entries beginning with term: Vascular
- BPD (bronchopulmonary dysplasia), *see* Chronic
lung disease
- BPF (bradykinin potentiating factor), discovery of,
ACE and, 8
- BPP (bradykinin potentiating peptide), ACE and,
8-9
- BPP_{5a} (bradykinin potentiating peptide_{5a}), 9
- Bradykinin potentiating factor (BPF), discovery of,
ACE and, 8
- Bradykinin potentiating peptide (BPP), ACE and,
8-9
- Bradykinin potentiating peptide_{5a} (BPP_{5a}), 9
- Brain, *see* Fetal brain
- Brain damage, *see* Cerebral palsy; Fetal brain
damage; Neurological injury, fetal and
neonatal
- Branched chain amino acid (BCAA) disorders,
neonatal hypoglycemia associated with, 173-
177
with 3-hydroxy-3-methylglutaryl coenzyme A lyase
deficiency, 174-175, 187
with MMA, 176-177, 187
with MSUD, 173-174, 187
with propionic acidemia, 175-176, 187
- Breech presentation with CP, 198
- Bronchopulmonary dysplasia, *see* Chronic lung
disease
- BWS (Beckwith-Wiedemann syndrome), *see*
Hypoglycemia, neonatal, in BWS
- C-5 (and C-6) of glucose, hydrogen on, in GNG
measurement, 99-100
- Calcium
fetal and neonatal hypocalcemia in diabetic
pregnancy, 129-130
preeclampsia therapy with, 33-36
- Calcium channel blockers, effects of, on 24-hour
pattern of hypertension, 285
- Captopril, 9 BPP_{5a} and metal-chelating agents in
development of, 9

- Carbohydrate metabolism, neonatal, *see* Neonatal carbohydrate metabolism
- Carbon recycling, glucose, neonatal GNG and, 103-104
- Cardiac defects
 four-chamber view of heart in detection of, 331-332; *see also* Four-chamber view of fetal heart with routine midtrimester screening
 see also Cardiac defects, and nuchal translucency thickness; Congenital heart disease; Fetal heart rate patterns, and CP; Genetic counseling for fetal congenital heart defects and specific defects
- Cardiac defects, and nuchal translucency thickness, 344-348
 category of, 346-347
 limitations of studies linking, 347-348
 relationship between, 344-346
- Cardiovascular physiology in pregnancy, 11-13
- Carnitine/acylcarnitine translocase deficiency, neonatal hypoglycemia associated with, 184, 186, 187
- Carnitine/palmitoyl transferase I (and II) deficiency, neonatal hypoglycemia associated with, 187-189
- Caspases, inhibition of, by NO, apoptosis and, 48-49
- CDH, *see* Congenital diaphragmatic hernia, neonatal
- Cellular basis of circadian timing, 243-246
- Cellular signaling with cGMP and NO, 2-6
 arginine effects on NO-cGMP formation and NOS, 3-4
 NO and prodrug effects on cGMP, 2-3
 soluble guanylate cyclase and, 2
- Cerebral glucose, *see* Glucose metabolism in developing brain
- Cerebral palsy (CP)
 introduction to, 195
 risk factors for, and conditions associated with, 196-199
 see also Fetal asphyxia; Fetal heart rate patterns, and CP; Infection, CP and; Markers of asphyxia in CP; Neonatal asphyxia; Neurological injury, CP and timing of fetal and neonatal
- Cerebrospinal fluid (CSF) glial fibrillary acidic protein and aspartic acid, as markers of neurological injury, 208
- cGMP (cyclic guanosine monophosphate)
 NO-mediated antiproliferation of VSCMs through pathway independent of, 52
 signal pathway dependent on, and NO role in apoptosis, 49
 see also Cellular signaling with cGMP and NO
- CHD (congenital heart disease), *see* Fetal congenital heart disease; Neonatal congenital heart disease
- Chelating agents, metal, BPP_{9a} and, in captopril development, 9
- Children
 chronopharmacotherapy of, 286-287
 melatonin administration to, 263-264
- Chorioamnionitis, maternal, anti-inflammatory therapy of, to prevent CLD, 447
- Chromosomes
 abnormal, congenital heart defects with, 375
 fetus with normal, nuchal translucency thickness and cardiac defects in, 347
- Chronic lung disease (CLD), 445-462
 epidemiology and pathogenesis of, 445-447
 prevention of, *see* Antenatal prevention of CLD; Postnatal prevention of CLD
 summary of, 457-458
- Chronobiology
 as background to chronopharmacology, 281
 cellular and molecular basis of circadian timing in, 243-246
 introduction to, 231
 role of melatonin secretion in, 310-311; *see also* Melatonin, physiology, production, and pharmacology of
 see also Arousal states, developmental perspective on regulation of; Chronopharmacology and chronopharmacotherapy; Circadian rhythmicity, development of; Light, physiologic effects of, on circadian pacemaker; Light in NICU, effects of, on preterm infants; Resetting circadian pacemaker with light
- Chronopharmacology and chronopharmacotherapy, 280-290
 of asthma bronchiale, 282-283
 for children, 286-287
 chronobiological background to, 281
 of hypertension, 284-286
 of peptic ulcer disease, 283-284
- Circadian oscillator, 301-304
 amplitude of, 303-304
 period of, 301-302
 phase of, 302-303
- Circadian pacemaker, *see* Light, physiologic effects of, on circadian pacemaker; Resetting circadian pacemaker with light
- Circadian rhythmicity, development of, 232-242
 and light-dark cycle influences on developing infant, 239
 nonphotic influences on, 239-240
 in preterm infants, 238; *see also* Light in NICU, and circadian rhythmicity development in preterm infants
 in primates, *see* Primates, circadian rhythmicity development in
 in rodents, 234-235
- Circadian timing, cellular and molecular basis of, 243-246
- Circuitry(ies)
 fast computer-controlled feedback, in patient-initiated mechanical ventilation, 433-439
 neural, for regulation of arousal states, 272-276
- Circulating blood, daily pattern of melatonin concentrations in, 311
- Circulation, maternal, *see* Maternal circulation
- CK (creatine phosphokinase), cord blood, as marker of neurological injury, 208

- CLD, *see* Chronic lung disease
- Clinical applications
- of nuchal translucency thickness, 348-349
 - see also* Clinical applications of PFC liquid ventilation
- Clinical applications of PFC liquid ventilation, 401-402
- for CDH, 423
 - non-respiratory, 401-402
 - in radiographic imaging, as anti-inflammatory agent, and in lung expansion, 402
 - respiratory, 401
- Clinical definitions of neonatal hypoglycemia, 140-141
- Clinical implications
- of neurological injury, 208
 - of physiologic effects of light on circadian pacemaker, 311-312
- Clinical trials
- of inhaled NO for newborns, meta-analysis of, 60-63
 - of PFC liquid ventilation in neonates, 402-403
- Clock, biological, *see* Biological clock
- Coagulopathy, ECMO for, 407
- Coenzyme A (CoA), *see* 3-Hydroxy-acyl-coenzyme A dehydrogenase deficiency, neonatal hypoglycemia associated with; 3-Hydroxy-3-methylglutaryl coenzyme A lyase deficiency; Medium chain acyl-coenzyme A dehydrogenase deficiency; Multiple acyl-coenzyme A dehydrogenase deficiency; Very long chain acyl-coenzyme A dehydrogenase deficiency
- Complications
- ECMO, 412
 - preventing premature delivery, and CLD prevention, 447
 - see also specific conditions*
- Computed tomography (CT)
- of neonatal hypoglycemia, 116-117
 - of neonatal neurological injury, 208-209
- Computer-assisted mechanical ventilation, *see* Mechanical ventilation, computer-assisted neonatal
- Congenital anomalies
- lethal, ECMO for, 407
 - see also specific congenital anomalies*
- Congenital diaphragmatic hernia (CDH), neonatal, 418-428
- etiology and embryology of, 420-421
 - historical perspective on, 418-420
 - iNO for, 423-424
 - neuromuscular blockade in, 422
 - pathophysiology of, 421
 - summary on, 425-426
 - surfactant therapy for, 424
 - surgery of, *see* Surgery of CDH
 - ventilation for, *see* Congenital diaphragmatic hernia, neonatal, ventilation for
- Congenital diaphragmatic hernia (CDH), neonatal, ECMO for
- benefits of, 423
 - ECMO patient management, 411-412
- Congenital diaphragmatic hernia (CDH), neonatal, ventilation for, 422-424
- HFOV, 423
- hyperventilation and alkalinization to permissive hypercapnia, 422-423
 - mechanical ventilation, 422
 - PFC liquid ventilation and ITPV, 424
 - see also* Congenital diaphragmatic hernia, neonatal, ECMO for
- Congenital heart disease, *see* Fetal congenital heart disease; Neonatal congenital heart disease
- Congenital hyperinsulinism, *see* Hyperinsulinism, neonatal
- Congenital malformations
- with CP, 197
 - in diabetic pregnancy, 124-125
 - see also* Cardiac defects
- Conventional therapy, *see* Medical therapy
- Conventional ventilation, *see* Mechanical ventilation, neonatal
- Cord blood arginine-vasopressin (AVP), as marker of neurological injury, 208
- Cord blood creatine phosphokinase (CK), as marker of neurological injury, 208
- Cord erythropoietin, as marker of neurological injury, 208
- Cord hypoxanthine, as marker of neurological injury, 208
- Coronary arteries, *see* Endothelium-derived hyperpolarizing factor in coronary arteries
- Counseling, *see* Genetic counseling for fetal congenital heart defects
- CP, *see* Cerebral palsy
- Creatine phosphokinase (CK), cord blood, as marker of neurological injury, 208
- Crux of heart, evaluation of, with routine midtrimester screening, 341-342
- CSF (cerebrospinal fluid) glial fibrillary acidic protein and aspartic acid, as marker of neurological injury, 208
- CT, *see* Computed tomography
- Cycles
- light, *see* Light-dark cycles
 - VSMC, NO regulation of, 52-53
- Cyclic guanosine monophosphate, *see* cGMP
- Cytochrome P450 metabolite, *see* Endothelium-derived hyperpolarizing factor in coronary arteries
- Cytoprotective proteins, NO-induced, apoptosis and, 48
- Cytotoxicity, nitrosative and oxidative stress in, 20-23
- DA (dopaminergic) arousal system, 272-276
- Daily pattern of melatonin concentrations in circulating blood, circadian pacemaker resetting and, 311
- Damage and injury, *see* Cerebral palsy; Neurological injury, fetal and neonatal; Retinal light damage
- Dark-light cycles, *see* Light-dark cycles

- Daughter blood vessels, formation of, VPF/VEGF and, 77
- Decidual-placental tissues, oxidative stress/oxidized lipids in, in preeclampsia, 30
- Degradation of fatty acids, *see* Mitochondrial β -oxidation and fatty acid degradation, neonatal hypoglycemia associated with defective
- Delivery
- CP and fetal presentation at, 198
 - premature, preventing complications of, to prevent CLD, 447
 - severe asphyxia proximate to, guidelines for identification of, 206
- Demographics of ECMO, 413-416
- Design of ventilators used in computer-assisted mechanical ventilation, 430-432, 435-436
- Deuterium labeled water, neonatal GNG measurement with, 99-100
- Development
- fetal brain, 204-205; *see also* Glucose metabolism in developing brain
 - of melatonin rhythmicity, 258-261
 - of preeclampsia, role of lipid oxidation and oxidative lipid derivatives in, 29-32
 - see also* Circadian rhythmicity, development of; Development, infant; Fetal development
- Development, infant
- light-dark cycle influences on, 239
 - visual system, in preterm infants, effects of light on, 294-296
 - see also* Arousal states, developmental perspective on regulation of; Rhythmicity development
- Developmental neurobehavioral model of increased reactivity to arousal, 276-277
- Diabetic pregnancy, fetal and neonatal effect(s) of, 120-135
- congenital malformations as, 124-125
 - fetal asphyxia and distress as, 123-124
 - hyperbilirubinemia and polycythemia as, 130
 - hypocalcemia and hypomagnesemia as, 129-130
 - hypoglycemia as, 128-129; *see also* Hypoglycemia, neonatal
 - long-term prognosis of, and follow-up on, 130-132
 - macrosomia as, 125-127
 - metabolic effects, 120-122
 - perinatal mortality as, 122-123
 - RDS as, 127
- Diagnosis
- of CP-causing intrauterine infections, 200
 - see also* Assessment; Fetal diagnosis; Laboratory diagnosis of neonatal hypoglycemia associated with organic and amino acid disorders; Neonatal diagnosis; Ultrasound and specific conditions
- Diaphragmatic hernia, *see* Congenital diaphragmatic hernia, neonatal
- Differential diagnosis, preoperative, between neonatal diffuse and focal HI, 158-159
- Diffuse hyperinsulinism (HI), neonatal, 155, 158-159
- Disadvantages of transvaginal US of fetal heart, 354
- Discontinuation of iNO therapy, 389-390
- Diseases
- treated with ECMO, 408-409
 - see also* Associated conditions, neonatal and specific conditions
- Distress, fetal, in diabetic pregnancy, 123-124
- Diuretic therapy, postnatal, in CLD prevention, 457
- Dopaminergic (DA) arousal system, 272-276
- Doppler ultrasound (US) of fetal heart, 354-355
- Dose
- of light in NICU, effects of, on preterm infant, 291-293
 - recommended iNO, 388-389
- Dose response curves (DRCs) to light, pacemaker resetting and, 308-309
- Drugs, *see* Medical therapy and specific drugs
- Duct, normal, on practical fetal heart scan, 329
- Duration
- of iNO therapy, 389
 - of ventilation before ECMO initiation, 407
- Dysmorphia, neonatal onset of MADD with and without, 184-186
- Dysplasia, bronchopulmonary, *see* Chronic lung disease
- Early fetal age, effects of, on obtaining four-chamber view of heart during midtrimester screening, 333
- Early fetal development, GNG in, 95-96
- ECMO, *see* Extracorporeal membrane oxygenation for neonates
- EDHF, *see* Endothelium-derived hyperpolarizing factor in coronary arteries
- EDRF (endothelium-derived relaxing factor), *see* Nitric oxide
- EEG (electroencephalogram) of neonatal neurological injury, 211
- Efferent pathways of SCN, 301
- Electroencephalogram (EEG) of neonatal neurological injury, 211
- Embryology of CDH, 420-421
- Encephalopathy, *see* Neurological injury, fetal and neonatal
- Endothelial dysfunction, preeclampsia and, 25
- Endothelial growth factor, *see* Vascular endothelial growth factor
- Endothelial nitric oxide synthase (eNOS), rapid activation of, 70-73
- ER α and, 71-72
 - by estrogen, 70-71
 - signal transduction in, 72-73
- Endothelium
- estrogen receptors in, 70-74
 - microvascular, VPF/VEGF actions on, 76
 - see also* Endothelium-derived hyperpolarizing factor in coronary arteries; Endothelium-derived vasoactive substances, free radicals and and entries beginning with term: Endothelial
- Endothelium-derived hyperpolarizing factor (EDHF) in coronary arteries, 15-19
- characterization of, 16-17
 - interaction between NO and, 17-18
- Endothelium-derived relaxing factor, *see* Nitric oxide

- Endothelium-derived vasoactive substances, free radicals and
ER β and, 66-69
estrogen receptors in endothelium and, 70-74
and hemodynamic changes in pregnancy, 11-14
history and relevance of ACEs and, 7-10
introduction to, 1
see also Angiogenesis; Nitric oxide; Nitric oxide synthase; Pregnancy
- eNOS, *see* Endothelial nitric oxide synthase, rapid activation of
- Entrainment, photic
24-hour day, and resetting of circadian pacemaker with light, 304-306
see also Entrainment, photic, and circadian rhythmicity development
- Entrainment, photic, and circadian rhythmicity development
in preterm infants in NICU, 250
in primates, 235-236
- Environmental light, *see* Light
- Enzymes, *see* Gluconeogenesis, neonatal, enzyme gene expression in *and specific enzymes*
- Epidemiology
of CLD, 445-447
of neonatal hypoglycemia, 141
see also Incidence
- ER(s) [estrogen receptor(s)] in endothelium, 70-74
- ER α , *see* Estrogen receptor α
- ER β (estrogen receptor β), 66-69
- Erythropoietin, cord, as marker of neurological injury, 208
- Estrogen
and NO-mediated processes in vasculature, 70
in rapid eNOS activation, 70-71
- Estrogen receptor(s) (ERs)
in endothelium, 70-74
see also Estrogen receptor α ; Estrogen receptor β
- Estrogen receptor α (ER α), 66-68
in rapid eNOS activation, 71-72
- Estrogen receptor β (ER β), 66-69
- Etiology
of CDH, 420-421
of congenital heart defects, genetic counseling exploration of possible, 374-376
neonatal HI of unknown, 161
of neonatal hypoglycemia in BWS, 166-168
see also specific conditions
- Evaluation
of PAV, 436-439
see also Assessment; Diagnosis
- Expectant management of fetal supraventricular tachycardias, 365-366
- Experience of technicians, effects of, on obtaining four-chamber view of heart during midtrimester screening, 333
- Expressed circadian rhythmicity, development of, in primates, 236-238
- Extracorporeal membrane oxygenation (ECMO) for neonates, 406-417
background of, 406-407
for CDH, *see* Congenital diaphragmatic hernia, neonatal, ECMO for
changing demographics for, 413-416
complications of, 412
diseases treated with, 408-409
duration of ventilation prior to, 407
and ECMO team, 409
indications for, 407-408
patient management, 409-412
the procedure, 409
survival with, and outcome of, 412-413
- Extrasystoles, isolated, fetal supraventricular tachycardias and, 360-362
- Eyes, neonatal, *see* Neonatal eyes
- Families, *see* Genetic counseling for fetal congenital heart defects
- Fast computer-controlled feedback circuitries, patient-initiated mechanical ventilation and, 433-439
- Fatty acids, *see* Mitochondrial β -oxidation and fatty acid degradation, neonatal hypoglycemia associated with defective
- Feedback circuitries, fast computer-controlled, in patient-initiated mechanical ventilation, 433-439
- Fetal age, *see* Gestational age
- Fetal asphyxia
in diabetic pregnancy, 123-124
severe, proximal to delivery, guidelines for identification of, 206
see also Acute asphyxia, fetal, in CP, diagnosis of; Fetal asphyxia, CP and, and FHR patterns
- Fetal asphyxia, CP and, and FHR patterns, 223-226
Hon patterns, 225-226
- Fetal brain
development of, 204-205; *see also* Glucose metabolism in developing brain
see also Fetal brain damage; Neurological injury, fetal and neonatal
- Fetal brain damage
in acute asphyxia, fetal diagnosis of, with meconium-stained amniotic fluid, 206
subsequent to reactive admission test, 223-225
see also Fetal diagnosis of neurological injury; Neurological injury, fetal and neonatal
- Fetal congenital heart disease (CHD)
diagnosis of, *see* Four-chamber view of fetal heart; New imaging modality(ies) of fetal heart; Nuchal translucency thickness; Practical fetal heart scan
introduction to, 323
outcome of, 380-384
see also Fetal supraventricular tachycardias; Genetic counseling for fetal heart congenital defects
- Fetal development
brain, 204-205
early, GNG in, 95-96
see also Glucose metabolism in developing brain
- Fetal diagnosis
of atrial flutter and atrial fibrillation and, 369

- of CHD, *see* Four-chamber view of fetal heart; New imaging modality(ies) of fetal heart; Nuchal translucency thickness; Practical fetal heart scan
- of extrasystoles, 360
- of supraventricular tachycardias, 362-363
- see also* Acute asphyxia, fetal, in CP, diagnosis of; Fetal diagnosis of neurological injury and specific conditions
- Fetal diagnosis of neurological injury, 205-208
 - acid/base status and, 207
 - FHR patterns in, 205, 206
 - intrapartum, 206
 - with meconium-stained amniotic fluid, 206
 - with nucleated RBCs and lymphocytes, 207-208
 - with ultrasound, 205-206
- Fetal distress in diabetic pregnancy, 123-124
- Fetal effects of diabetic pregnancy, *see* Diabetic pregnancy, fetal and neonatal effect(s) of
- Fetal gluconeogenesis (GNG), 95-98
 - in early fetal development, 95-96
 - GNG enzyme gene expression and, 96-98
- Fetal heart, *see* Fetal congenital heart disease; Fetal heart rate patterns, and CP
- Fetal heart rate (FHR) patterns, and CP, 221-229
 - asphyxia and, *see* Fetal asphyxia, CP and, and FHR patterns
 - neonatal associations with, 227
 - in neurological injury diagnosis, 205, 206
 - persistent nonreactive, 226-227
 - reactive admission test and, 222-225
- Fetal hyperbilirubinemia in diabetic pregnancy, 130
- Fetal hypocalcemia in diabetic pregnancy, 129-130
- Fetal hypoglycemia in diabetic pregnancy, 128-129
- Fetal hypomagnesemia in diabetic pregnancy, 129-130
- Fetal markers of asphyxia in CP, 215-216
- Fetal neurological injury, *see* Neurological injury, fetal and neonatal
- Fetal onset of adult disease, melatonin and, 261
- Fetal polycythemia in diabetic pregnancy, 130
- Fetal position, effects of, on obtention of four-chamber view of heart in routine midtrimester screening, 333
- Fetal presentation, CP and, 198
- Fetal respiratory distress syndrome (RDS) in diabetic pregnancy, 127
- Fetal supraventricular tachycardias, 360-372
 - atrial flutter and atrial fibrillation and, 369-371
 - diagnosis of, 362-363
 - isolated extrasystoles and, 360-362
 - management of, 363-368
- Fetal surgery for CDH, 424-425
- Fetal ultrasound, *see* Ultrasound, fetal
- Fetus, *see* Antenatal prevention of CLD and entries beginning with terms: Fetal, Intrauterine
- FHR, *see* Fetal heart rate patterns, and CP
- Fibrillary acidic protein, CSF glial, as marker of neurological injury, 208
- Fibrillation and flutter, atrial, supraventricular tachycardias and, 369-371
- FiO₂ (fraction of inspired oxygen) adjustment of, to control SpO₂ in computer-assisted mechanical ventilation, 430-432
- Flow-volume loops, monitoring of, in computer-assisted mechanical ventilation, 442
- Fluid management, postnatal, in CLD prevention, 457
- Flutter and fibrillation, atrial, supraventricular tachycardias and, 369-371
- Focal adenomatous hyperplasia, *see* Focal hyperinsulinism, neonatal
- Focal hyperinsulinism (HI), neonatal, 155-159
 - natural history of, 157-158
 - origin of, 155-156
 - preoperative differentiation between diffuse and, 158-159
 - treatment of, 158
- Focal hyperplasia, neonatal, *see* Focal hyperinsulinism, neonatal
- Follow-up
 - on fetal and neonatal effects of diabetic pregnancy, 130-132
 - on neonatal hypoglycemia, 145-147
- Four-chamber view of fetal heart
 - normal, on practical fetal heart scan, 325-327
 - see also* Four-chamber view of fetal heart with routine midtrimester screening
- Four-chamber view of fetal heart with routine midtrimester screening, 331-342
 - accuracy of cardiac defects detected with, 331-332
 - of aortic outflow tract, 333-334
 - of crux of heart, 341-342
 - factors affecting ability to obtain, 332-333
 - of great vessels and axis, 341
 - of pulmonary artery, 334-336
 - of ventricles, 337-341
- Fraction of inspired oxygen (FiO₂) adjustment of, to control SpO₂ in computer-assisted mechanical ventilation, 430-432
- Free radicals, *see* Endothelium-derived vasoactive substances, free radicals and
- Frequency
 - of mutations in neonatal hypoglycemia, 179
 - of neonatal hypoglycemia in BWS, 164-165
- Frequency (electricity)
 - transducer, effects of, on obtention of four-chamber view of heart during midtrimester scan, 333
 - see also* High frequency ventilation
- Gastroesophageal reflux (GER), CDH and, 421
- Gastrointestinal pathophysiology in CDH, 421
- Gated three-dimensional ultrasound (US; 3DUS), nongated versus, fetal heart imaging with, 356
- GC (guanylate cyclase), soluble, and cellular signaling with cGMP and NO, 2
- GDH (glutamate dehydrogenase) mutation, neonatal atypical HI due to, 159-161
- Gene therapy, *see* Nitric oxide synthase gene therapy of vascular pathology

- Genetic counseling for fetal congenital heart defects, 373-379
 exploration of possible etiology in, 374-376
 psychosocial needs of families addressed in, 376-377
 risks of recurrence assessed in, 377-378
- Genetic disorders
 associated with congenital heart defects, 375
 see also Gluconeogenesis, neonatal, enzyme gene expression in; Hyperinsulinism, neonatal; Hypoglycemia, neonatal, associated with organic and amino acid disorders; Hypoglycemia, neonatal, in BWS and entries beginning with term: Congenital
- Genetics, 187
 of MCAD deficiency, 179, 187
 see also Chromosomes; Genetic disorders; Knockout animals; Mutations; Nitric oxide synthase gene therapy of vascular pathology; Phenotype(s); Vascular endothelial growth factor gene family expressed in placenta, placental angiogenesis and
- GER (gastroesophageal reflux), CDH and, 421
- Gestational age
 and ECMO use, 407
 effects of, on obtention of four-chamber view of heart during midtrimester scanning, 333
 optimal, for three-dimensional US, 357
 and use of iNO, 388
- GK (glucokinase) mutation, neonatal atypical HI due to, 159-160
- Glial fibrillary acidic protein, CSF, as marker of neurological injury, 208
- Glucocorticoid therapy, CLD prevention with antenatal, 447
 see also Glucocorticoid therapy, postnatal, CLD prevention with
- Glucocorticoid therapy, postnatal, CLD prevention with, 452-454
 inhaled, 453-454
 systemic, 452-453
- Glucokinase (GK) mutation, neonatal atypical HI due to, 159-160
- Gluconeogenesis (GNG), neonatal, 94-106
 from alanine, 101-102
 fetal and, *see* Fetal gluconeogenesis
 glucose and, *see* Glucose, neonatal GNG and
 from glycerol, 101
 GNG enzyme gene expression and, *see* Gluconeogenesis, neonatal, enzyme gene expression in
 from lactate, 102
 quantifying, *see* Gluconeogenesis, quantification of neonatal
- Gluconeogenesis (GNG), neonatal, enzyme gene expression in, 96-98
 G-6-Pase, 97-98
 PC, 96
 PEPCK, 96-97
- Gluconeogenesis (GNG), quantification of neonatal, 98-100
 with deuterium labeled water, 99-100
 with mass isotopomer distribution analysis, 98-99
 with tracer methods, 8
- Glucose, neonatal GNG and, 102-104
 glucose carbon recycling, 102-103
 methodological issues in measurement of, to define hypoglycemia, 139-140
 total GNG contribution to glucose production, 103-104
- Glucose carbon recycling, and neonatal GNG, 102-103
- Glucose metabolism
 neonatal hypoglycemia and disturbances in, 137-138; *see* Hypoglycemia, neonatal
 see also Glucose metabolism in developing brain
- Glucose metabolism in developing brain, 107-115
 alternate substrates for, 111-112
 cerebral glucose utilization and, 107-108
 glucose transporter proteins and, 108-111
 hypoxia-ischemia and substitute fuels for, 112-114
- Glucose-6-phosphatase (G-6-Pase) gene expression, gluconeogenesis and, 97-98
- Glucose transporter proteins, and glucose metabolism in developing brain, 108-111
- Glutamate dehydrogenase (GDH) mutation, neonatal atypical HI due to, 159-161
- Glutaric aciduria type 2 (multiple acyl-coenzyme A dehydrogenase deficiency), neonatal hypoglycemia associated with, 183-187
- Glycerol, neonatal GNG from, 101
- GNG, *see* Gluconeogenesis, neonatal
- G-6-Pase (glucose-6-phosphatase) gene expression, gluconeogenesis and, 97-98
- Great vessels, evaluation of, with routine midtrimester screening, 341
- Growth, *see* Development
- Growth factor, *see* Vascular endothelial growth factor
- Guanosine monophosphate, cyclic, *see* cGMP
- Guanylate cyclase (GC), soluble, and cellular signaling with NO and cGMP, 2
- Guides and guidelines
 computer programs as clinician, to computer-assisted mechanical ventilation, 442-443
 for identification of severe asphyxia proximate to delivery, 206
- H (hydrogen) on C-5 and C-6 of glucose in GNG measurement, 99-100
- Heart, *see* Congenital heart disease; Fetal heart rate patterns, and CP
- Hemodynamic changes in pregnancy, endothelium-derived vasoactive substances and, 11-14
- Hemoglobin oxygen saturation (SpO₂), arterial, adjustment of FiO₂ to control, in computer-assisted mechanical ventilation, 430-432
- Hemorrhage, intracranial, ECMO for, 407
- Heredity, *see* Genetics
- Hernia, *see* Congenital diaphragmatic hernia, neonatal
- HFOV, *see* High frequency oscillatory ventilation
- HI, *see* Hyperinsulinism, neonatal

- High frequency oscillatory ventilation (HFOV)
for CDH, 423
iNO with, 390-391
- High frequency ventilation
versus mechanical ventilation, in CLD prevention, 450
see also High frequency oscillatory ventilation
- High-output nitric oxide (NO), preferred source of arginine for, in blood vessels, 42-45
- Histology of neonatal hyperinsulinism, 151
- History
of ACEs, 7-10
of CDH, 418-420
natural, of neonatal focal HI, 157-158
of physiologic effects of light on circadian pacemaker, 300
- Hon pattern of asphyxia in CP, FHR patterns and, 225-226
- Human chronobiology, *see* Chronobiology
- Hydrogen (H) on C-5 and C-6 of glucose in GNG measurement, 99-100
- 3-Hydroxy-acyl-coenzyme A dehydrogenase deficiency, neonatal hypoglycemia associated with, 182-187
long-chain, 182-183, 185, 187
short-chain, 184, 186
- 3-Hydroxy-3-methylglutaryl coenzyme A lyase deficiency, neonatal hypoglycemia associated with, 174-175, 187
- Hyperbilirubinemia, fetal and neonatal, in diabetic pregnancy, 130
- Hypercapnia, hyperventilation and alkalization to permissive, in CDH, 422-423
- Hyperinsulinism (HI), neonatal, 150-163
atypical, 159-161
autosomal recessive, due to mutations in beta cell K_{ATP} channel genes, 152-153, 158
diagnosis of, 151, 158-159
diffuse, 155, 158-159
focal, *see* Focal hyperinsulinism, neonatal
histology of, 151
therapy of, *see* Therapy and management of neonatal HI
of unknown etiology, 161
- Hyperpermeability, microvascular, to plasma proteins, VPF and, 76-77
- Hyperplasia
intimal, NOS gene therapy of, 51-52
neonatal focal, *see* Focal hyperinsulinism, neonatal
- Hyperpolarizing factor, *see* Endothelium-derived hyperpolarizing factor in coronary arteries
- Hypertension
chronopharmacotherapy of, 284-286
persistent pulmonary, in CDH, 421
- Hyperventilation, alkalization and, to permissive hypercapnia in CDH, 422-423
- Hypocalcemia, fetal and neonatal, in diabetic pregnancy, 129-130
- Hypoglycemia
fetal, in diabetic pregnancy, 128-129
see also Hypoglycemia, neonatal
- Hypoglycemia, neonatal, 116-119, 136-149, 164-193
associated with organic and amino acid disorders, *see* Hypoglycemia, neonatal, associated with organic and amino acid disorders
in BWS, *see* Hypoglycemia, neonatal, in BWS
current perceptions of, 137
definitions of, *see* Hypoglycemia, neonatal, definitions of
in diabetic pregnancy, 128-129
diagnosis of, *see* Neonatal diagnosis of hypoglycemia
pathogenesis and pathophysiology of, 137-139
PET for, 117-119
prognosis of, and follow-up on, 145-147
recurrent or persistent, 145
therapy and management of, *see* Therapy and management of neonatal hypoglycemia
- Hypoglycemia, neonatal, associated with organic and amino acid disorders, 172-193
with BCAA disorders, *see* Branched chain amino acid disorders, neonatal hypoglycemia associated with
with defective mitochondrial β -oxidation and fatty acid degradation, *see* Mitochondrial β -oxidation and fatty acid degradation, neonatal hypoglycemia associated with defective
with mitochondrial disorders, 3-MGC aciduria, 172
- Hypoglycemia, neonatal, in BWS, 164-171
etiology of, 166-168
evaluation and therapy of, 168-170
frequency of, 164-165
National Cancer Institute Registry of, 166
symptoms of, 165-166
- Hypoglycemia, neonatal, definitions of, 139-142
clinical definitions, 140-141
epidemiological definitions, 141
methodological issues in glucose measurement and, 139-140
operational thresholds in proposed operational definition, 142
physiologic definitions, 141-142
- Hypomagnesemia, fetal and neonatal, in diabetic pregnancy, 129-130
- Hypoxanthine, cord, as marker of neurological injury, 208
- Hypoxia-ischemia, and substitute fuels for glucose metabolism in developing brain, 112-114
- ICH (intracranial hemorrhage), ECMO for, 407
- Illumination intensity in NICU, effects of, on preterm infants, 294
- Incidence
of CLD by birth weight, 446
of heart abnormalities in population, effects of, on obtention of four-chamber view of heart during midtrimester screening, 333
- Indications
for ECMO, 407-408
see also Inhaled nitric oxide for neonates,

- recommendations for use of *and specific conditions*
- Individual differences in response to arousal, 270-271
- Infant(s), *see* Prematurity *and entries beginning with terms*: Intrauterine, Neonatal, Perinatal
- Infections
 - prevention of, in prevention of CLD, 457
 - see also* Infections, CP and
- Infections, CP and, 200-203
 - diagnosis of, 200
 - maternal intrauterine, 200-201
 - pathophysiology of neurological damage and infection, 202-203
- Inflammatory conditions, *see* Anti-inflammatory therapy
- Inhaled glucocorticoids, postnatal, CLD prevention with, 453-454
- Inhaled nitric oxide (iNO) for neonates, 55-65, 387-395
 - with ARDS, 56
 - background to, 387-388
 - biological functions of NO and, 55-56
 - with CDH, 423-424
 - CLD prevention with, 452
 - meta-analysis of controlled trials of, 60-63
 - for preterm infants, 63-64
 - pulmonary vascular disease prevented with, 57
 - recommendations for use of, *see* Inhaled nitric oxide for neonates, recommendations for use of
 - with respiratory failure, 57
 - summary of, 392-393
- Inhaled nitric oxide (iNO) for neonates,
 - recommendations for use of, 388-392
 - discontinuation of, 389-390
 - dose and, 388-389
 - duration of treatment and weaning from, 389
 - gestational and postnatal age and, 388
 - with HFOV, 390-391
 - illness severity and, 388
 - monitoring, 391
 - in non-ECMO centers and during transport, 391
 - potential iNO use in preterm neonates, 391-392
- Inheritance, *see* Genetics
- Initiation of ECMO, duration of ventilation before, 407
- Injury
 - prevention of pulmonary, due to mechanical ventilation and oxygen, and CLD prevention, 448-449
 - see also* Neurological injury, fetal and neonatal
- iNO, *see* Inhaled nitric oxide for neonates
- Inositol, postnatal, CLD prevention with, 456
- Inspiratory pressure, peak, adjustment of, to control tidal volume in computer-assisted mechanical ventilation, 432
- Inspired oxygen, fraction of, adjustment of, to control SpO₂ in computer-assisted mechanical ventilation, 430-432
- Intensity of illumination in NICU, effects of, on preterm infants, 294
- Intensive care unit, *see* Light in NICU, and circadian rhythmicity development in preterm infants;
Light in NICU, effects of, on preterm infants
- Intermittent light, circadian pacemaker resetting with, 310
- Intimal hyperplasia, NOS gene therapy of, 51-52
- Intracranial hemorrhage (ICH), ECMO for, 407
- Intrapartum diagnosis of neurological injury, 206
- Intratracheal pulmonary ventilation (ITPV)
 - for CDH, 424
 - postnatal CLD prevention with, 451
- Intrauterine infection, maternal, CP and, 200-201
- Intrauterine ultrasound (US) of fetal heart, 355
- Ionized calcium, serum, NO and, and preeclampsia, 34-35
- Ischemia-hypoxia, and substitute fuels for glucose metabolism in developing brain, 112-114
- Isoforms, NOS
 - physiologic roles of, 88
 - see also* Endothelial nitric oxide synthase, rapid activation of
- Isolated extrasystoles, fetal supraventricular tachycardias and, 360-362
- Isotopomer distribution analysis, mass, of neonatal GNG, 98-99
- ITPV, *see* Intratracheal pulmonary ventilation
- K_{ATP} gene mutations, beta cell channel, neonatal autosomal recessive hyperinsulinism due to, 152-155, 158
- Kinetics, lactate, and GNG from lactate, 102
- Knockout animals, NOS effects in, 87-90
- Labor, markers of asphyxia during, 216-217
- Laboratory diagnosis of neonatal hypoglycemia
 - associated with organic and amino acid disorders, 172-176, 180-183
 - with carnitine/palmitoyl transferase I (and II) deficiency, 188-189
 - with of 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency, 174-175
 - with LCHAD deficiency, 183
 - with MCAD deficiency, 180-181
 - with methylmalonic acidemia, 177
 - with 3-MGC aciduria, 172
 - with MSUD, 173-174
 - with propionic acidemia, 175-176
 - with VLCAD deficiency, 182
- Lactate, neonatal GNG from, 102
- Late onset of MADD, 184, 186
- LCHAD (long-chain-3-hydroxy-acyl-coenzyme A dehydrogenase) deficiency, neonatal hypoglycemia associated with, 182-183, 185, 187
- Left side of fetus, fetal heart seen on, on practical heart scan, 325
- Lethal congenital anomalies, ECMO for, 407
- Light
 - acute suppression of melatonin by, 311
 - see also* Entrainment, photic; Light, physiologic effects of, on circadian pacemaker; Light in

- NICU, and circadian rhythmicity
development in preterm infants; Light in
NICU, effects of, on preterm infants; Light-
dark cycles; Resetting circadian pacemaker
with light
- Light, physiologic effects of, on circadian
pacemaker, 299-320
characteristics of pacemaker, 301
circadian oscillator and, *see* Circadian oscillator
clinical implications of, 311-312
historical background to, 300
neuroanatomy of pacemaker, 300-301
and pacemaker resetting, *see* Resetting circadian
pacemaker with light
and role of melatonin secretion in chronobiology,
310-311; *see also* Melatonin, physiology,
production, and pharmacology of
- Light-dark cycles
influence of, on infant development, 239
melatonin role in translating information on, 310
in NICU, studies on, 250-255
- Light in NICU, and circadian rhythmicity
development in preterm infants, 247-257
cycled light studies, 250-255; *see also* Light-dark
cycles
issues influencing, 248-250
role of entrainment in, 250
- Light in NICU, effects of, on preterm infants, 291-
298
on developing visual system, 294-296
dose of, 291-293
illumination intensity and, 294
see also Light in NICU, and circadian rhythmicity
development in preterm infants
- Linear response to arousal, 271-272
- Lipid(s), oxidative lipid derivatives and oxidation of,
in preeclampsia development, 29-32
- Liquid ventilation, *see* Perfluorochemical liquid
ventilation, neonatal
- Long-chain-3-hydroxy-acyl-coenzyme A
dehydrogenase (LCHAD) deficiency,
neonatal hypoglycemia associated with, 182-
183, 185, 187
- Long-term medical therapy of neonatal
hyperinsulinism, 152
- Long-term prognosis of diabetic pregnancy, 130-132
- Low birth weight
associated with CP, 197
gluconeogenesis in VLBW infants, 103, 104
- Lungs, *see* Ventilation, neonatal and entries beginning
with terms: Pulmonary, Respirator, Respiratory
- Lymphocytes in fetal neurological injury diagnosis,
207-208
- Macrosomia in diabetic pregnancy, 125-127
- MADD (multiple acyl-coenzyme A dehydrogenase
deficiency), neonatal hypoglycemia associated
with, 183-187
- Magnetic resonance imaging (MRI)
of fetal heart, 357
see also Magnetic resonance imaging, neonatal
- Magnetic resonance imaging (MRI), neonatal
of hypoglycemia, 116-117
of neurological injury, 209-211
- MAPK (mitogen activated protein kinase), p42/44,
in NO-mediated antiproliferation of VSMCs,
53
- Maple syrup urine disease (MSUD), neonatal
hypoglycemia associated with, 173-174, 187
- Markers of asphyxia in CP, 215-219
at birth, 217-218
fetal, 215-216
during labor, 216-217
neonatal, 218-219
- Mass isotopomer distribution analysis, neonatal
GNG measurement with, 98-99
- Maternal abdominal surgery, effects of, on
obtention of four-channel view of heart
during routine midtrimester screening, 333
- Maternal chorioamnionitis, anti-inflammatory
therapy of, to prevent CLD, 447
- Maternal circulation
systemic, oxidative stress/oxidized lipids in, in
preeclampsia, 30-31
VEGF and PlGF in, 85
- Maternal conditions associated with CP, 196-197
- Maternal intrauterine infections, CP and, 200-201
- Maternal obesity, effects of, on obtention of four-
chamber view of heart during midtrimester
screening, 332-333
- Mathematical models of circadian pacemaker
resetting, 310
- MCAD (medium chain acyl-coenzyme A
dehydrogenase) deficiency, neonatal
hypoglycemia associated with, 179-181, 185,
187
- Mechanical ventilation, neonatal
neuromuscular blockade and, in CDH, 422
see also Mechanical ventilation, computer-assisted
neonatal; Mechanical ventilation, postnatal,
CLD prevention with
- Mechanical ventilation, postnatal, CLD prevention
with, 448-450
by preventing pulmonary injury due to ventilation
and/or oxygen, 448-449
versus high frequency ventilation, 450
- Mechanical ventilation, computer-assisted neonatal,
429-444
computer programs as clinician's guides to, 442-
443
patient-initiated, with fast computer-controlled
feedback circuitries, 433-439
respiratory monitoring and pulmonary function
testing during, 440-442
ventilator design in, 430-432, 435-436
weaning from, 439-440
- Meconium-stained amniotic fluid, fetal diagnosis of
brain injury with, 206
- Medical implications of physiologic effects of light
on circadian pacemaker, 311-313
- Medical therapy
of fetal supraventricular tachycardias, 366-367
long-term neonatal hyperinsulinism, 152

- see also* Chronopharmacology and chronopharmacotherapy; Prodrugs *specific conditions and specific therapeutic agents; for example*. Inhaled nitric oxide for neonates
- Medium chain acyl-coenzyme A dehydrogenase (MCAD) deficiency, neonatal hypoglycemia associated with, 179-181, 185, 187
- Melatonin, physiology, production, and pharmacology of, 258-266
and development of melatonin rhythmicity, 258-261
fetal onset of adult disease and, 261
and melatonin administration to children, 263-264
role of melatonin in chronobiology, 310-311
scoliosis and, 263-264
- Meta-analysis of controlled trials of inhaled NO therapy in newborns, 60-63
- Metabolic effects, fetal and neonatal, of diabetic pregnancy, 120-122
- Metabolism, carbohydrate, *see* Neonatal carbohydrate metabolism
- Metal-chelating agents, captopril and, 9
- Methodological issues in glucose measurement, hypoglycemia definition and, 139-140
- 3-Methylglutaconic (3-MGC) aciduria, neonatal hypoglycemia associated with, 172
- Methylmalonic acidemia (MMA), neonatal hypoglycemia associated with, 176-177, 187
- 3-MGC (3-methylglutaconic) aciduria, neonatal hypoglycemia with, 172
- Microvascular endothelium, VPF/VEGF actions on, 76
- Microvascular hyperpermeability to plasma proteins, VPF and, 76-77
- Midtrimester screening of fetal heart, *see* Four-chamber view of fetal heart with routine midtrimester screening
- Minute ventilation, respirator rate adjustment to control, in computer-assisted mechanical ventilation, 432
- Mitochondrial disorders, neonatal hypoglycemia associated with, 172
- Mitochondrial β (beta)-oxidation and fatty acid degradation, neonatal hypoglycemia associated with defective, 177-189
with carnitine/acylcarnitine translocase deficiency, 184, 186, 187
with carnitine/palmitoyl transferase I (and II) deficiency, 187-189
with LCHAD deficiency, 182-183, 185, 187
with MADD deficiency, 183-187
with MCAD deficiency, 179-181, 185, 187
with SCHAD deficiency, 184, 186
with VLCAD deficiency, 181-182, 185, 187
- Mitogen activated protein kinase (MPAK), p42/44, in NO-mediated antiproliferation of VSMCs, 53
- MMA (methylmalonic acidemia), neonatal hypoglycemia associated with, 176-177, 187
- Model(s)
developmental neurobehavioral, of increased reactivity to arousal, 276-277
mathematical, of circadian pacemaker resetting, 310
- Molecular basis of circadian timing, 243-246
- Molecular clock, *see* Biological clock
- Monitoring
of iNO therapy, 391
of PFC liquid ventilation, 399-400
respiratory and pulmonary function, in computer-assisted mechanical ventilation, 440-442
- Monophosphate, cyclic guanosine, *see* cGMP
- Mortality
ECMO for lethal congenital anomalies, 407
perinatal, in diabetic pregnancy, 122-123
see also specific conditions
- Mother blood vessels, formation of, VPF/VEGF and, 77
- MPAK (mitogen activated protein kinase), p42/44, in NO-mediated antiproliferation of VSMCs, 53
- MRI, *see* Magnetic resonance imaging
- MSUD (maple syrup urine disease), neonatal hypoglycemia associated with, 173-174, 187
- Multifetal gestations, CP associated with, 198
- Multiple acyl-coenzyme A dehydrogenase deficiency (MADD; glutaric aciduria type 2), neonatal hypoglycemia associated with, 183-187
- Mutations
in neonatal hypoglycemia, 179, 187
see also Mutations in neonatal HI
- Mutations in neonatal HI
beta cell K_{ATP} channel gene, and neonatal autosomal recessive hyperinsulinism, 152-155, 158
GDH, atypical neonatal HI and, 159-161
- National Cancer Institute Registry of neonatal hypoglycemia in BWS, 166
- Natural history of neonatal focal HI, 157-158
- NE (norepinephrine) arousal system, 272-276
- Neonatal asphyxia in CP, markers of, 218-219
- Neonatal associated conditions, *see* Associated conditions, neonatal
- Neonatal carbohydrate metabolism
introduction to, 91-93
see also Diabetic pregnancy, fetal and neonatal effect(s) of; Gluconeogenesis, neonatal; Glucose metabolism in developing brain; Hyperinsulinism, neonatal; Hypoglycemia, neonatal
- Neonatal chronobiology, *see* Chronobiology
- Neonatal congenital diaphragmatic hernia, *see* Congenital diaphragmatic hernia, neonatal
- Neonatal congenital heart disease (CHD), ECMO for, 407
- Neonatal development, *see* Development, infant
- Neonatal diagnosis
of HI, 151, 158-159
see also Neonatal diagnosis of hypoglycemia;

- Neonatal diagnosis of neurological injury and specific conditions
- Neonatal diagnosis of hypoglycemia
in BWS, 168-170
see also Laboratory diagnosis of neonatal hypoglycemia associated with organic and amino acid disorders; Tomography of neonatal hypoglycemia
- Neonatal diagnosis of neurological injury, 208-211
with CT, 208-209
with EEG, 211
with MRI, 209-211
with ultrasound, 208
- Neonatal eyes
light dose to, in NICU, 293
see also Light in NICU, effects of, on preterm infants; Retinal light damage; Retinopathy of prematurity
- Neonatal hyperbilirubinemia in diabetic pregnancy, 130
- Neonatal hyperinsulinism, *see* Hyperinsulinism, neonatal
- Neonatal hypocalcemia in diabetic pregnancy, 129-130
- Neonatal hypoglycemia, *see* Hypoglycemia, neonatal
- Neonatal hypomagnesemia in diabetic pregnancy, 129-130
- Neonatal inhaled nitric oxide, *see* Inhaled nitric oxide for neonates
- Neonatal intensive care unit, *see* Light in NICU, and circadian rhythmicity development in preterm infants; Light in NICU, effects of, on preterm infants
- Neonatal magnetic resonance imaging, *see* Magnetic resonance imaging, neonatal
- Neonatal markers of asphyxia in CP, 218-219
- Neonatal neurological injury, *see* Neurological injury, fetal and neonatal
- Neonatal onset of MADD with and without dysmorphism, 184-186
- Neonatal polycythemia in diabetic pregnancy, 130
- Neonatal respiratory disease, management of introduction to, 385-386
see also Chronic lung disease; Congenital diaphragmatic hernia, neonatal; Extracorporeal membrane oxygenation for neonates; Inhaled nitric oxide for neonates; Mechanical ventilation, neonatal; Perfluorochemical liquid ventilation, neonatal
- Neonatal respiratory distress syndrome (RDS) in diabetic pregnancy, 127
- Neonatal respiratory failure, inhaled NO for, 57
- Neonates, *see* Inhaled nitric oxide for neonates; Prematurity and entries beginning with terms: Neonatal, Perinatal
- Neural circuitry for regulation of arousal states, 272-276
- Neuroanatomy
of circadian pacemaker, 300-301
neuroanatomical pathways of melatonin production, 310-311
- Neurobehavioral model, developmental, of increased reactivity to arousal, 276-277
- Neurobiology of hypoglycemia, 138-139
- Neurological injury, CP and timing of fetal and neonatal, 204-214
brain development and, 204-205
causes of injury, 205
clinical information on CP and, 208
fetal diagnosis of, *see* Fetal diagnosis of neurological injury
five factors in determination of, 224
neonatal diagnosis of, *see* Neonatal diagnosis of neurological injury
pathological evidence of, 212
- Neurological injury, fetal and neonatal infections and, 201-203
see also Cerebral palsy; Fetal brain damage; Neurological injury, CP and timing of fetal and neonatal
- Neuromuscular blockade in CDH, 422
- New imaging modality(ies) of fetal heart, 352-359
Doppler US as, 354-355
intrauterine US as, 355
magnetic resonance imaging as, 357
three-dimensional US, 355-357
transvaginal US as, 352-354
- Newborns, *see* Prematurity and entries beginning with terms: Intrauterine, Neonatal, Perinatal
- NICU (neonatal intensive care unit), *see* Light in NICU, and circadian rhythmicity development in preterm infants; Light in NICU, effects of, on preterm infants
- Nitric oxide (NO; endothelium-derived relaxing factor)
arginine as preferred source for high-output synthesis of, in blood vessels, 42-45
biological functions of, inhaled NO and, 55-56; *see also* Inhaled nitric oxide for neonates and effects of oxidative and nitrosative stress in cytotoxicity, 20-23
interaction between EDHF and, 17-18
p42/44 MAPK in VSMC antiproliferation mediated by, 53
peroxynitrite and, in perinatal period, 37-41
preeclampsia, calcium and, 33-36
see also Cellular signaling with cGMP and NO; Inhaled nitric oxide for neonates; Nitric oxide, role of, in apoptosis
- Nitric oxide (NO; endothelium-derived relaxing factor), role of, in apoptosis, 46-50
apoptosis described, 46-47
cGMP-dependent signal pathway and, 49
inhibition of caspases by NO and, 48-49
NO as apoptosis inducer, 47
NO as apoptosis suppressor, 47-48
and NO-induced cytoprotective proteins, 48
- Nitric oxide synthase (NOS)
arginine effects on, 3-4
effects of, in knockout animals, 87-90
see also Endothelial nitric oxide synthase, rapid activation of; Nitric oxide synthase gene therapy of vascular pathology

- Nitric oxide synthase (NOS) gene therapy of
 vascular pathology, 51-54
 for intimal hyperplasia, 51-52
 NO-mediated VSMC antiproliferation and, *see*
 Vascular smooth muscle cells, NO-mediated
 antiproliferation of
- Nitrosative stress in cytotoxicity, 20-23
- NO, *see* Nitric oxide
- Non-extracorporeal membrane oxygenation
 (ECMO) centers, iNO therapy in, 391
- Nongated three-dimensional ultrasound (US), gated
 versus, for fetal heart imaging, 356
- Nonlinear response to arousal, 271-272
- Nonphotic influences
 on developing circadian rhythmicity, 239-240
 on plasma melatonin concentrations, 311
- Nonreactive fetal heart rate (FHR) patterns,
 persistent, in CP, 226-227
- Non-respiratory clinical applications of PFC liquids,
 401-402
- Norepinephrine (NE) arousal system, 272-276
- Normal arch on practical fetal heart scan, 329
- Normal duct on practical fetal heart scan, 329
- Normal four-chamber view on practical fetal heart
 scan, 325-327
- Normal ventriculo-arterial connections on practical
 fetal heart scan, 327-329
- Normal visual system development in preterm
 infants, light and, 294-295
- NOS, *see* Nitric oxide synthase
- Nuchal cord, tightness of, associated with CP, 199
- Nuchal translucency thickness, 343-351
 cardiac defects and, *see* Cardiac defects, and
 nuchal translucency thickness
 clinical applications of, 348-349
 pathophysiology of, 348
 perinatal outcome and, 347
- Nucleated red blood cells (RBCs) in diagnosis of CP
 due to asphyxia, 219
 due to fetal brain injury, 207-208
- Nutrition
 and calcium supplementation in preeclampsia,
 33-36
 in CLD prevention, 456-457
- O₂, *see* Oxygen
- Obesity, effects of maternal, on obtention of four-
 chamber view of heart during midtrimester
 screening, 332-333
- Onset
 fetal, of adult disease, melatonin and, 261
 of neonatal MADD with and without dysmorphia,
 184-186
- Operational definition of neonatal hypoglycemia,
 proposed, operational thresholds in, 142
- Ophthalmic sequelae of prematurity, 295-296
- Optimal fetal age for three-dimensional US, 357
- Organic disorders, *see* Hypoglycemia, neonatal,
 associated with organic and amino acid
 disorders and specific disorders
- Oscillator, circadian, *see* Circadian oscillator
- Oscillatory ventilation, *see* High frequency oscillatory
 ventilation
- Outcome
 of ECMO, 412-413
 fetal atrial flutter and atrial fibrillation, 369-371
 of fetal congenital heart defects, 380-384
 fetal extrasystole, 361
 fetal supraventricular tachycardia, 368-369
 see also Mortality; Patient survival; Perinatal
 outcome; Prognosis *specific conditions and*
 therapeutic modalities
- Outflow of aortic tract, routine midtrimester
 screening of, 333-334
- Ovaries
 pathophysiology of, 80
 physiology of, 79-80
- Oxidation
 and degradation of fatty acids, *see* Mitochondrial
 β -oxidation and fatty acid degradation,
 neonatal hypoglycemia associated with
 defective
 lipid, oxidative lipid derivatives and, in
 preeclampsia development, 29-32
- Oxidative lipid derivatives, lipid oxidation and, in
 preeclampsia development, 29-32
- Oxidative stress
 as clinical sign of preeclampsia, 31; *see also*
 Oxidative stress, oxidized lipids and, in
 preeclampsia
 in cytotoxicity, 20-23
 as linkage between reduced placental perfusion
 and preeclampsia, 26-27
- Oxidative stress, oxidized lipids and, in
 preeclampsia, 30-31
- in decidual-placental tissues, 30
- in systemic maternal circulation and tissues, 30-31
- Oxygen (O₂)
 fraction of inspired, adjustment of, to control
 SpO₂ in computer-assisted mechanical
 ventilation, 430-432
 prevention of pulmonary injury due to, and CLD
 prevention, 448-449
- Oxygenation, *see* Extracorporeal membrane
 oxygenation for neonates; Ventilation,
 neonatal
- p42/44 mitogen activated protein kinase (MPAK) in
 NO-mediated antiproliferation of VSMCs, 53
- PA (propionic acidemia), neonatal hypoglycemia
 associated with, 175-176, 187
- Pacemaker, *see* Light, physiologic effects of, on
 circadian pacemaker; Resetting circadian
 pacemaker with light
- Palmitoyl transferase I (and II)/carnitine deficiency,
 neonatal hypoglycemia associated with, 187-
 189
- Palsy, *see* Cerebral palsy
- Pancreatectomy, partial, for neonatal
 hyperinsulinism, 152
- Partial liquid ventilation (PLV), 398-401
 described, 398-399

- PFC liquid conservation during, 400
TLV compared with, 400-401
- Partial pancreatectomy for neonatal hyperinsulinism, 152
- Pathology and pathophysiology
of CDH, 421
of CLD, 445-447
of CP, 212
of 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency, 174
of MADD, 183-184
of methylmalonic acidemia, 176
of 3-MGC aciduria, 172
of MSUD, 173
of neonatal hypoglycemia, 137-139
of neurological damage and infection in CP, 202-203
of nuchal translucency thickness, 348
of preeclampsia, 25, 29-30
of propionic acidemia, 175
reproductive, angiogenesis and, 80, 81
see also Nitric oxide synthase gene therapy of vascular pathology and specific conditions
- Patient-initiated mechanical ventilation, fast computer-controlled feedback circuitries and, 433-439
- Patient survival with ECMO, 412-413
- Patient-triggered ventilation (PTV), CLD prevention with, 450-451
- PAV, *see* Proportional assist ventilation
- PC (pyruvate carboxylase) gene expression, gluconeogenesis and, 96
- Peak inspiratory pressure, adjustment of, to control tidal volume in computer-assisted mechanical ventilation, 432
- PEPCK (phosphoenol pyruvate carboxykinase) gene expression, gluconeogenesis and, 96-97
- Peptic ulcer disease, chronopharmacotherapy of, 283-284
- Peptides, *see* Bradykinin potentiating peptide; Bradykinin potentiating peptide_{5a}
- Perfluorochemical (PFC) liquid ventilation, neonatal, 396-405
clinical applications of, *see* Clinical applications of PFC liquid ventilation
clinical trials with, 402-403
conclusion on, 404
monitoring, 400
partial, *see* Partial liquid ventilation
postnatal CLD prevention with, 451-452
properties of PFC liquids, 397
rationale for, 396-397
total, *see* Total liquid ventilation
weaning from, 399-400
- Perfusion, placental, oxidative stress as linkage between preeclampsia and reduced, 30
- Perinatal mortality in diabetic pregnancy, 122-123
- Perinatal outcome
with diabetic pregnancy, 122-123
nuchal translucency thickness and, 347
- Perinatal period, peroxyntirite and NO in, 37-41
- Period (τ) of circadian oscillator, 301-302
- Perioperative management of neonatal CDH, 421-422
- Permeability factor, vascular, *see* Vascular endothelial growth factor
- Permissive hypercapnia, hyperventilation and alkalization to, in CDH, 422-423
- Peroxyntirite, NO and, in perinatal period, 37-41
- Persistent hypoglycemia, neonatal, 145
- Persistent nonreactive fetal heart rate (FHR)
patterns in CP, 226-227
- Persistent pulmonary hypertension (PPHN) in CDH, 421
- PET (positron emission tomography) for neonatal hypoglycemia, 117-119
- PFC, *see* Perfluorochemical liquid ventilation, neonatal
- PIGF gene expression
in maternal circulation, 85
in placenta, 84
- Pharmacology, *see* Chronopharmacology and chronopharmacotherapy; Medical therapy; Melatonin, physiology, production, and pharmacology of; Prodrugs
- Phase (ϕ)
of circadian oscillator, 302-303
type I versus type 0, circadian pacemaker resetting and, 308
- Phase-angle (ψ) of circadian oscillator, 301
- Phase response curves (PRCs) of circadian pacemaker, pacemaker resetting and, 307-308
- Phenotype(s)
carnitine/palmitoyl transferase I and II deficiency, 187-188
in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency, 174
LCHAD deficiency, 182-183
in 3-MGC aciduria, 172
MMA, 176
in MSUD, 173
of NOS knockout animals, 88
in propionic acidemia, 175
in VLCAD deficiency, 181-182
- Phosphoenol pyruvate carboxykinase (PEPCK) gene expression, gluconeogenesis and, 96-97
- Photoc entrainment, *see* Entrainment, photic
- Physical properties of PFC liquids, 397-398
- Physiologic background of PAV, 434-435
- Physiologic target variables, slowly changing, control of, in computer-assisted mechanical ventilation, 430-432
- Physiologic definitions of neonatal hypoglycemia, 141-142
- Physiologic effects of light, *see* Light, physiologic effects of, on circadian pacemaker
- Physiologic responses to arousal, 268-269
- Physiologic roles of NOS isoforms, 88
- Physiology
blood vessel, in NOS knockout mice, 87-90
and hemodynamic changes in pregnancy, 11-14
of melatonin, *see* Melatonin, physiology, production, and pharmacology of

- reproductive, angiogenesis and, 79-81
see also entries beginning with term: Physiologic
- Pineal melatonin, *see* Melatonin, physiology, production, and pharmacology of
- Placenta
 abnormal, associated with CP, 198-199
see also entries beginning with term: Placental
- Placental angiogenesis, *see* Vascular endothelial growth factor gene family expressed in placenta, placental angiogenesis and
- Placental perfusion, reduced, oxidative stress as linkage between preeclampsia and, 26-27
- Placental tissues, decidual-, oxidative stress/oxidized lipids in, in preeclampsia, 30
- Plasma melatonin, effects of nonphotic stimuli on concentrations of, 311
- Plasma proteins, microvascular hyperpermeability to, VPF and, 76-77
- PLV, *see* Partial liquid ventilation
- Polycythemia, fetal and neonatal, in diabetic pregnancy, 130
- Position
 effects of fetal, on obtaining four-chamber view of heart during midtrimester screening, 333
 four-chamber, on practical fetal heart scan, 325
- Positron emission tomography (PET) of neonatal hypoglycemia, 117-119
- Postnatal age, and use of iNO, 388
- Postnatal prevention of CLD, 448-452
 with antioxidants, 454
 with fluid management and diuretic therapy, 457
 with glucocorticoids, *see* Glucocorticoid therapy, postnatal, CLD prevention with
 infection and sepsis prevention and, 457
 with iNO, 452
 with inositol and α_1 -proteinase inhibitor, 456
 role of nutrition in, 456-457
 with surfactant therapy, 450
 with ventilation, *see* Postnatal prevention of CLD with ventilation
- Postnatal prevention of CLD with ventilation, 450-452
 with high frequency ventilation, 450
 with ITPV, 451
 with PFC liquid ventilation, 451-452
 with PTV, 450-451
see also Mechanical ventilation, postnatal, CLD prevention with
- Potentiating peptides, *see* Bradykinin potentiating peptide; Bradykinin potentiating peptide_{5a}
- PPHN (persistent pulmonary hypertension) in CDH, 421
- Practical fetal heart scan, 324-330
 heart on left side of fetus on, 325
 normal arch and duct on, 329
 normal four-chamber view on, 325-327
 normal ventriculo-arterial connections on, 327-329
- PRCs (phase response curves) to light, circadian pacemaker resetting and, 307-308
- Preeclampsia
 calcium, NO and, 33-36
 pathology and pathophysiology of, 25, 29-30
 role of lipid oxidation and oxidative lipid derivatives in development of, 29-32
see also Preeclampsia, and endothelium-derived vasoactive substances
- Preeclampsia, and endothelium-derived vasoactive substances, 24-28
 atherosclerosis and, 25
 endothelial dysfunction and, 25
 and impact of preeclampsia, 24
 and oxidative stress as linkage between reduced placental perfusion and preeclampsia, 26-27
 pathology of preeclampsia, 25
 stages of, 26
- Pregnancy
 hemodynamic changes in, endothelium-derived vasoactive substances and, 11-14
see also Diabetic pregnancy, fetal and neonatal effect(s) of; Preeclampsia *entries beginning with term:* Maternal and specific aspects of pregnancy
- Prematurity
 association between CP and, 197
 ophthalmic sequelae of, 295-296
 preventing adverse effects of premature delivery and, and CLD in prevention, 447
see also Preterm infants
- Prenatal conditions and interventions, *see* Antenatal prevention of CLD and *entries beginning with terms:* Fetal, Intrauterine
- Preoperative differential diagnosis between neonatal diffuse and focal HI, 158-159
- Preterm infants
 circadian rhythmicity development in, 238; *see also* Light in NICU, and circadian rhythmicity development in preterm infants; Light in NICU, effects of, on preterm infants
see also Low birth weight; Prematurity; Preterm infants, iNO for
- Preterm infants, iNO for, 63-64
 potential iNO use in, 391-392
- Prevalence of cardiac anomalies, relationship between nuchal translucence thickness and, 346
- Prevention
 of CLD, *see* Antenatal prevention of CLD; Postnatal prevention of CLD
 of pulmonary vascular disease with inhaled NO, 57
- Primates, circadian rhythmicity development in, 233-238
 expressed rhythmicity, 236-238
 photic entrainment and, 235-236
 SCN development and, 235
- Prodrugs, effects of, on cGMP cellular signaling, 2-3
- Prognosis
 of diabetic pregnancy, 130-132
 of 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency, 175
 of LCHAD deficiency, 183
 of MADD, 184
 of MCAD deficiency, 181
 of 3-MGC aciduria, 172

- of MMA, 177
- of MSUD, 174
- of neonatal hypoglycemia, 145-147
- of PA, 176
- of VLCAD deficiency, 182
- see also Outcome and specific conditions*
- Programs, computer, as clinician guides to
 - computer-assisted ventilation, 442-443
- Propionic acidemia (PA), neonatal hypoglycemia associated with, 175-176, 187
- Proportional assist ventilation (PAV), 434-439
 - evaluation of, 436-439
 - physiologic background of, 434-435
 - ventilator design with PAV capacity, 435-436
- Protein(s)
 - CSF glial fibrillary acidic, as marker of neurological injury, 208
 - glucose transporter, and glucose metabolism in developing brain, 108-111
 - NO-induced cytoprotective, apoptosis and, 48
 - plasma, VPF and microvascular hyperpermeability to, 76-77
- Protein kinase, p42/44 mitogen activated, in NO-mediated antiproliferation of VSMCs, 53
- α (alpha)-Proteinase inhibitor, postnatal, CLD prevention with, 456
- Psychosocial needs of fetal congenital heart defect patients' families, genetic counseling addressing, 376-377
- PTV (patient-triggered ventilation), CLD prevention with, 450-451
- Pulmonary artery, evaluation of, with routine midtrimester screening, 334-336
- Pulmonary expansion with PFC liquids, 402
- Pulmonary function testing with computer-assisted mechanical ventilation, 440-442
- Pulmonary hypertension, persistent, in CDH, 421
- Pulmonary injury due to mechanical ventilation and oxygen, preventing, to prevent CLD, 448-449
- Pulmonary pathophysiology in CDH, 421
- Pulmonary vascular disease, inhaled NO in prevention of, 57
- Pulmonary ventilation, *see* Intratracheal pulmonary ventilation
- Pyruvate carboxylase (PC) gene expression, gluconeogenesis and, 96
- Quantitative measurements of fetal heart with three-dimensional US, 357
- Radiographic imaging with PFC liquids, 401-402
- RBCs (red blood cells), *see* Nucleated red blood cells in diagnosis of CP
- RDS, *see* Respiratory distress syndrome, neonatal
- Reactive admission test in CP, 222-225
- Reactivity to arousal models, developmental neurobehavioral model of increased, 276-277
- Real-time three-dimensional three-dimensional ultrasound (US) of fetal heart, 356-357
- Recessive hyperinsulinism (HI), neonatal autosomal, due to mutations in beta cell K_{ATP} channel genes, 152-153, 158
- Recurrence
 - of fetal congenital heart defect, genetic counseling assessing risks of, 377-378
 - of neonatal hypoglycemia, 145
- Red blood cells, *see* Nucleated red blood cells in diagnosis of CP
- Refractory fetal supraventricular tachycardias, management of, 367-368
- Reproductive physiology, angiogenesis and, 79-81
- Resetting circadian pacemaker with light, 304-310
 - dose-response curves to light and, 308-309
 - with intermittent light, 310
 - maintenance of 24-hour entrainment in, 304-306
 - mathematical models of, 310
 - PRCs to light and, 307-308
 - wavelength effects on, 309-310
- Respirator rate, adjustment of, to control minute ventilation in computer-assisted mechanical ventilation, 432
- Respiratory applications of PFC liquid ventilation, 401
- Respiratory disease, *see* Neonatal respiratory disease, management of
- Respiratory distress syndrome (RDS), neonatal
 - acute, inhaled NO for, 56
 - fetal and neonatal, in diabetic pregnancy, 127
 - see also* Neonatal respiratory disease, management of
- Respiratory failure, neonatal
 - inhaled NO for, 57
 - see also* Neonatal respiratory disease, management of
- Respiratory monitoring in computer-assisted mechanical ventilation, 440-442
- Retinal light damage in preterm infants, visual system development and, 295
- Retinopathy of prematurity (ROP), and visual system development in preterm infants, 295
- Rhythmicity development
 - melatonin, 258-261
 - see also* Circadian rhythmicity, development of
- Risk and risk factors
 - at-risk infants for hypoglycemia, 143
 - for CP, 196-199
 - for recurrence of fetal congenital heart defect, genetic counseling assessing, 377-378
- Rodents, developing circadian rhythmicity in, 234-235
- ROP (retinopathy of prematurity), and visual system development, 295
- Routine midtrimester screening of fetal heart, *see* Four-chamber view of fetal heart with routine midtrimester screening
- SCHAD (short-chain-3-hydroxy-acyl-coenzyme A dehydrogenase) deficiency, neonatal hypoglycemia associated with, 184, 186
- SCN, *see* Suprachiasmatic nuclei
- SCN (suprachiasmatic nuclei) clock, 243-245
- Scoliosis, melatonin and, 263-264
- Second messenger, NO as, 4

- Sensitivity
 of four-chamber view of heart in routine midtrimester screening, 332
 of screening for cardiac defects using nuchal translucency thickness, 345
- Sepsis
 prevention of, in prevention of CLD, 457
 see also Infections
- Serum ionized calcium, NO and, preeclampsia, 34-35
- Severe asphyxia proximate to delivery, guidelines for identification of, 206
- Severity of respiratory disease, and use of iNO, 388
- sGC (soluble guanylate cyclase), discovery of, cellular signaling with NO and cGMP and, 2
- Shift workers, physiologic effects of light on circadian system of, 312-313
- Short-chain-3-hydroxy-acyl-coenzyme A dehydrogenase (SCHAD) deficiency, neonatal hypoglycemia associated with, 184, 186
- Signal pathways, cGMP-dependent, and NO role in apoptosis, 49
- Signal transduction in eNOS rapid activation, 72-73
- Signaling, cellular, *see* Cellular signaling with cGMP and NO
- Signs and symptoms, *see* Symptoms of neonatal hypoglycemia
- Single-gene disorders associated with congenital heart defects, 375
- Size, four-chamber, on practical fetal heart scan, 325
- Slowly changing physiologic target variables, control of, in computer-assisted mechanical ventilation, 430-432
- Smooth muscle cells, *see* Vascular smooth muscle cells
- SOD (superoxide dismutase), postnatal, CLD prevention with, 455-456
- Soluble guanylate cyclase (sGC), and cellular signaling with NO and cGMP, 2
- SpO₂ (arterial hemoglobin oxygen saturation), adjustment of FiO₂ to control, in computer-assisted mechanical ventilation, 430-432
- Stages of preeclampsia, 26
- Stanford cycled light trials, and circadian rhythmicity development, 250-251
- Stress
 nitrosative, in cytotoxicity, 20-23
 oxidative, *see* Oxidative stress
- Structure, heart, *see* Practical fetal heart scan
- Substitute fuels for glucose metabolism in developing brain, hypoxia-ischemia and, 112-114
- Substrates, alternate glucose metabolism, in developing brain, 111-112
- Superoxide dismutase (SOD), postnatal, CLD prevention with, 455-456
- Supplementation, *see* Nutrition
- Suprachiasmatic nuclei (SCN), 300-301
 afferent and efferent pathways of, 301
 development of, in primates, 235
- Suprachiasmatic nuclei (SCN) clock, 243-245
- Supraventricular tachycardias, *see* Fetal supraventricular tachycardias
- Surfactant therapy
 of CDH, 424
 postnatal, in prevention of CLD, 450
- Surgery
 of CDH, *see* Surgery of CDH
 maternal abdominal, effects of, on obtention of four-chamber view of heart during midtrimester screening, 333
 partial pancreatectomy for neonatal hyperinsulinism, 152
- Surgery of CDH
 fetal, 424-425
 neonatal, perioperative management and, 421-422
- Symptoms of neonatal hypoglycemia
 in BWS, 165-166
 Whipple's Triad and, 140-141
- Systemic glucocorticoids, postnatal, CLD prevention with, 452-453
- Systemic maternal circulation and tissues in preeclampsia, oxidative stress/oxidized lipids in, 30-31
- Tachycardias, *see* Fetal supraventricular tachycardias
- Team, ECMO, 409
- Technicians' experience, effects of, on obtention of four-chamber view of heart during midtrimester screening, 333
- Teratogens associated with congenital heart defects, 374
- Therapy and management
 of fetal atrial flutter and atrial fibrillation and, 369
 of fetal extrasystoles, 361
 of preeclampsia with calcium supplementation, 33-36
 of supraventricular tachycardias, 363-368
 see also Chronopharmacology and chronopharmacotherapy; Inhaled nitric oxide for neonates; Medical therapy; Neonatal respiratory disease, management of; Prevention; Surgery; Therapy and management of neonatal HI; Therapy and management of neonatal hypoglycemia and specific conditions
- Therapy and management of neonatal HI, 151-152
 due to beta cell K_{ATP} channel gene mutations, 158
 with long-term medical therapy or partial pancreatectomy, 152
- Therapy and management of neonatal hypoglycemia, 142-143
 with BWS, 168-170
 due to carnitine/palmitoyl transferase I (and II) deficiency, 189
 due to 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency, 175
 due to LCHAD deficiency, 183
 due to MADD, 184
 due to MCAD deficiency, 181

- due to 3-MGC aciduria, 172
 - due to MMA, 177
 - due to MSUD, 174
 - due to PA, 176
 - due to VLCAD deficiency, 182
- Thickness of nuchal translucency, *see* Nuchal translucency thickness
- Three-dimensional ultrasound (US) of fetal heart, 355-357
- Thyrotropin releasing hormone (TRH) therapy, antenatal, in CLD prevention, 447-448
- Tidal volume
 - adjustment of peak inspiratory pressure to control, in computer-assisted mechanical ventilation 432
 - monitoring airway pressure relationship to, 441-442
- Tightness of nuchal cord associated with CP, 199
- Timing of neurological injury, *see* Neurological injury, CP and timing of fetal and neonatal
- Tissues in preeclampsia, oxidative stress/oxidized lipids in, 20
 - decidual-placental, 30
 - systemic maternal, 30-31
- TLV, *see* total liquid ventilation
- Tomography of neonatal hypoglycemia, 116-119
 - computer, 116-117
 - positron emission, 117-119
- Total gluconeogenesis (GNG), contribution of, to neonatal glucose production, 103-104
- Total liquid ventilation (TLV)
 - described, 398
 - PFC liquid conservation during, 400
 - PLV compared with, 400-401
- Tracer methods, neonatal GNG measurement with, 98
- Transducer frequency, effects of, on four-chamber view of heart during midtrimester screening, 333
- Translucency, *see* Nuchal translucency thickness
- Transport, iNO therapy during, 391
- Transporter proteins, glucose, and glucose metabolism in developing brain, 108-111
- Transvaginal ultrasound (US) of fetal heart, 352-354
- Treatment, *see* Therapy and management
- TRH (thyrotropin releasing hormone) therapy, antenatal, CLD prevention with, 447-448
- 24-hour day entrainment, and circadian pacemaker resetting, 304-306
- 24-hour pattern of hypertension, effects of calcium channel blockers and ACE inhibitors on, 285
- Type 1 versus type 0 phase, circadian pacemaker resetting and, 308
- Ulcer disease, peptic, chronopharmacotherapy of, 283-284
- Ultrasound (US)
 - neonatal, of neurological injury, 208
 - see also* Ultrasound, fetal
- Ultrasound (US), fetal
 - of neurological injury, 205-206
 - see also* Ultrasound, fetal heart
- Ultrasound (US), fetal heart, 352-357
 - Doppler, 354-355
 - intrauterine, 355
 - three-dimensional, 355-357
 - transvaginal, 352-354
- Umbilical cord, *see* entries beginning with term: Cord
- Unknown etiology, neonatal hyperinsulinism of, 161
- US, *see* Ultrasound
- Uterus
 - pathophysiology of, 81
 - physiology, 80-81
- Vascular disease
 - pulmonary, inhaled NO in prevention of, 57
 - see also* Nitric oxide synthase gene therapy of vascular pathology
- Vascular endothelial growth factor (VEGF; vascular permeability factor)
 - angiogenic response to, 75-78
 - see also* Vascular endothelial growth factor gene family expressed in placenta, placental angiogenesis and
- Vascular endothelial growth factor (VEGF) gene family expressed in placenta, placental angiogenesis and, 82-86
 - PIGF, 84
 - and receptor expression, 84-85
 - VEGF-A and, *see* Vascular endothelial growth factor-A gene expression
- Vascular endothelial growth factor-A (VEGF-A) gene expression, 83-85
 - in maternal circulation, 85
 - in placenta, 83-84
- Vascular permeability factor, *see* Vascular endothelial growth factor
- Vascular smooth muscle cells (VSMCs)
 - NO regulating cycle of, 52-53
 - see also* Vascular smooth muscle cells, NO-mediated antiproliferation of
- Vascular smooth muscle cells (VSMCs), NO-mediated antiproliferation of
 - through cGMP-independent pathway, 52
 - p42/44 MPAK in, 53
- Vasculature
 - estrogen and NO-mediated processes in, 71-72
 - see also* Blood vessels and entries beginning with term: Vascular
- Vasoactive substances, *see* Endothelium-derived vasoactive substances, free radicals and
- Vasopressin, arginine-, cord blood, as marker of neurological injury, 208
- VEGF, *see* Vascular endothelial growth factor
- VEGF-A, *see* Vascular endothelial growth factor-A gene expression
- Ventilation, neonatal
 - duration of, before ECMO initiation, 407
 - see also* Congenital diaphragmatic hernia, neonatal, ventilation for; Extracorporeal membrane oxygenation for neonates; High frequency ventilation; Intratracheal

- pulmonary ventilation; Mechanical ventilation, neonatal; Perfluorochemical liquid ventilation, neonatal; Postnatal prevention of CLD with ventilation
- Ventricles, evaluation of, in routine midtrimester screening, 337-341
- Ventriculo-arterial connections, normal in, on practical fetal heart scan, 327-329
- Very long chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency, neonatal hypoglycemia associated with, 181-182, 185, 187
- Very low birth weight (VLBW) infants, gluconeogenesis in, 103, 104
- Visual system, effects of light on development of, in preterm infants, 294-296
- Vitamin A, postnatal, CLD prevention with, 454-455
- Vitamin C, postnatal, CLD prevention with, 455
- Vitamin E, postnatal, CLD prevention with, 455
- VLBW (very low birth weight) infants, gluconeogenesis in, 103, 104
- VLCAD (very long chain acyl-coenzyme A dehydrogenase) deficiency, neonatal hypoglycemia associated with, 181-182, 185, 187
- Volume
 - monitoring of flow-volume loops in computer-assisted mechanical ventilation, 442
 - tidal, *see* Tidal volume
 - volume/airway pressure relationship monitoring in computer-assisted mechanical ventilation, 441-442
- VPF (vascular permeability factor), *see* Vascular endothelial growth factor
- VSMCs, *see* Vascular smooth muscle cells
- Water, deuterium labeled, neonatal GNG measurement with, 99-100
- Wavelength of light, effects of, on circadian pacemaker resetting, 309-310
- Weaning
 - from computer-assisted mechanical ventilation, 439-440
 - from iNO therapy, 389
 - from PFC liquid ventilation, 399-400
- Weight, *see* Birth weight
- Whipple's Triad, and signs and symptoms of neonatal hypoglycemia, 140-141
- Workers, shift, physiologic effects of light on circadian system of, 312-313